Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.
Community, Culture, Applications & Research
Explore the main themes, entities and connections around Interferon beta-1a. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
interferon ms beta patients beta-1a interferons treatment drug avonex injection rebif produced may 30 therapy also multiple sclerosis beta-1b us
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Interferon beta-1a | AHFS/Drugs.com | Professional Drug Facts | 1.00 | infobox |
| Interferon beta-1a | ATC code | L03AB07 (WHO) | 1.00 | infobox |
| Interferon beta-1a | CAS Number | 145258-61-3 Y | 1.00 | infobox |
| Interferon beta-1a | ChEMBL | ChEMBL1201562 N | 1.00 | infobox |
| Interferon beta-1a | ChemSpider | none | 1.00 | infobox |
| Interferon beta-1a | DrugBank | DB00060 Y | 1.00 | infobox |
| Interferon beta-1a | Elimination half-life | 10 hrs | 1.00 | infobox |
| Interferon beta-1a | Formula | C908H1408N246O252S7 | 1.00 | infobox |
| Interferon beta-1a | IUPHAR/BPS | 8339 | 1.00 | infobox |
| Interferon beta-1a | KEGG | D04554 | 1.00 | infobox |
| Interferon beta-1a | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Interferon beta-1a | Legal status | US: ℞-only | 1.00 | infobox |
| Interferon beta-1a | Legal status | EU: Rx-only | 1.00 | infobox |
| Interferon beta-1a | License data | EU EMA: by INN | 1.00 | infobox |
| Interferon beta-1a | License data | US DailyMed: Interferon_beta-1a | 1.00 | infobox |
| Interferon beta-1a | MedlinePlus | a604005 | 1.00 | infobox |
| Interferon beta-1a | Molar mass | 20027.14 g·mol−1 | 1.00 | infobox |
| Interferon beta-1a | Pregnancy category | AU: D | 1.00 | infobox |
| Interferon beta-1a | Routes of administration | Subcutaneous, intramuscular | 1.00 | infobox |
| Interferon beta-1a | Trade names | Avonex, Rebif, Plegridy, others | 1.00 | infobox |
| Interferon beta-1a | UNII | XRO4566Q4R | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.